MAIA Biotechnology, Inc.

NYSE American MAIA

MAIA Biotechnology, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -1.34

MAIA Biotechnology, Inc. EPS (Diluted) is USD -1.34 for the Trailing 12 Months (TTM) ending September 30, 2024, a 11.84% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

MAIA Biotechnology, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.52, a -9.35% change year over year.
MAIA Biotechnology, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.39, a 15.37% change year over year.
MAIA Biotechnology, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.64.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NYSE American: MAIA

MAIA Biotechnology, Inc.

CEO	Dr. Vlad Vitoc M.B.A., M.D.
IPO Date	July 28, 2022
Location	United States
Headquarters	444 West Lake Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years